Table 1.
Comparison of clinicopathological data and short-term clinical outcome between qualified and not-qualified LND.
| Qualified n=138 | Not-qualified n=51 | ||
|---|---|---|---|
| Median (IQR),% | Median (IQR),% | P | |
| Age (years) | |||
| ≤65 | 69.4 | 64.7 | |
| >65 | 30.4 | 35.3 | 0.524 |
| Sex | |||
| Male | 65.4 | 58.8 | |
| Female | 34.6 | 41.2 | 0.426 |
| BMI | |||
| <25 | 83.3 | 80.4 | |
| ≥25 | 16.7 | 19.7 | 0.636 |
| ASA score | |||
| I | 28.3 | 19.6 | |
| II | 30.4 | 23.5 | |
| III–IV | 41.3 | 56.9 | 0.159 |
| ECOG score | |||
| 0 | 68.4 | 80 | |
| 1 | 24.8 | 10 | |
| 2 | 6.8 | 10 | 0.081 |
| Tumor size (mm) | |||
| <35 | 44.9 | 33.3 | |
| ≥35 | 55.1 | 66.7 | 0.013 |
| Clinical stages | |||
| II | 60.9 | 29.4 | |
| III | 39.1 | 70.6 | 0.012 |
| Event score grade | |||
| 1 | 29 | 2 | |
| 2 | 30.4 | 13.7 | |
| 3 | 31.9 | 17.6 | |
| 4 | 8.7 | 66.7 | 0.014 |
| Pathological data | |||
| Pathological stage | |||
| I | 14.5 | 2.0 | |
| II | 55.8 | 25.7 | |
| III | 29.7 | 72.5 | <0.001 |
| Total number of LN | 34 (27–43) | 36 (29–50) | 0.074 |
| Metastatic LN | 4 (1–5) | 14 (4–23) | <0.001 |
| Surgery time (min) | 67 (63–71) | 70 (66–76) | 0.002 |
| Estimated blood loss (ml) | 56 (30–58) | 80 (50–100) | <0.001 |
| Clinical outcome | |||
| Any 30 day complications | |||
| Yes | 17.4 | 29.4 | |
| No | 82.6 | 70.6 | 0.118 |
| Surgical Complications (%) | |||
| Yes | 4.3 | 13.7 | |
| No | 95.7 | 86.3 | 0.024 |
| Systemic complications | |||
| Yes | 13 | 15.7 | |
| No | 87 | 84.3 | 0.259 |
| Hospitalization time (days) | 10 (9–12) | 12 (10–14) | 0.003 |
The bold value represents the P value with statistical significance.
ASA, American Society of Anesthesiologists; ECOG, Eastern Cooperative Oncology Group; LN, Lymph node; LND, Lymph node dissection.